Brief: Summit Therapeutics Q2 Net Income USD -215.7 Million
23/07/2026 21:06
BRIEF-Summit Therapeutics Q2 Net Income USD -215.7 Million Jul 23 (Reuters) - Summit Therapeutics Q2 EPS USD -0.28.
- Q2 operating expenses USD 220.5 million
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)